KYMRIAH: Clinical Trials

11 trials of KYMRIAH, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 3 recruiting, 1 active not recruiting, 1 suspended. 6 Phase 1, 3 Phase 2, 1 Early Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 16Completed 3, Recruiting 2, Suspended 1
Phase 23Active not recruiting 1, Recruiting 1, Suspended 1
Early Phase 11Completed 1
Phase 31Withdrawn 1

Follow KYMRIAH: new trials by email Literature Review of KYMRIAH trials Research Report on KYMRIAH

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma
Biospecimen Collection, Computed Tomography, Cyclophosphamide - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Phase 1RecruitingNathan Denlinger182026-12-012026-10-09
Autologous CD22 CAR T Cells Following Commercial CD19 CAR T Cells in B Cell Malignancies
CD22CART infusion, Tisagenlecleucel - Leukemia, Acute Lymphoblastic Leukemia
Phase 1RecruitingStanford University282024-05-132026-09-01
Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
Axicabtagene Ciloleucel, Biospecimen Collection, Computed Tomography - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma
Phase 2RecruitingSWOG Cancer Research Network3962023-06-122026-10-15
Duvelisib Exposure to Enhance Immune Profiles of T Cells in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma, DEEP T CELLS Study
Duvelisib, Tisagenlecleucel - Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
Early Phase 1CompletedEmory University42022-01-132025-01-20
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
Efineptakin alfa, Tisagenlecleucel, Axicabtagene ciloleucel - Refractory Diffuse Large B-cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma
Phase 1CompletedNeoImmuneTech172021-07-292026-08-10
Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL
E7777, Fludarabine, Cyclophosphamide - DLBCL, Diffuse Large B Cell Lymphoma
Phase 1 / Phase 2SuspendedMasonic Cancer Center, University of Minnesota302021-06-092026-11-04
CAR T Cells Real World Evidence Study Based on the French Hospital Claims Data Source (PMSI)
KYMRIAH, YESCARTA - Diffuse Large B-Cell Lymphoma (DLBCL), Acute Lymphoblastic Leukemia (ALL)
CompletedNovartis Pharmaceuticals2732020-12-092022-07-01
Tisagenlecleucel vs Blinatumomab or Inotuzumab for Patients With Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia
Tisagenlecleucel, Blinatumomab, Inotuzumab - Acute Lymphoblastic Leukemia
Phase 3WithdrawnNovartis Pharmaceuticals2020-06-052020-07-09
Tisagenlecleucel In Primary CNS Lymphoma
Tisagenlecleucel - Primary CNS Lymphoma, Refractory Primary CNS Lymphoma
Phase 1CompletedMatthew J. Frigault, M.D.132019-01-012026-01-09
MT2017-45: CAR-T Cell Therapy for Heme Malignancies
KYMRIAH, YESCARTA, Fludarabine 30mg/m2 4 doses - Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
Phase 2Active not recruitingMasonic Cancer Center, University of Minnesota1502018-12-182026-01-23
CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies
Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis - Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia
Phase 1CompletedM.D. Anderson Cancer Center262015-12-162022-06-30

Conditions studied

Lymphoma, Large B-Cell, Diffuse (6)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (5)  ·  Leukemia (1)  ·  Leukemia, Biphenotypic, Acute (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Non-Hodgkin (1)  ·  Neoplasm, Residual (1)

Sponsors

Masonic Cancer Center, University of Minnesota (2)  ·  Novartis Pharmaceuticals (2)  ·  Emory University (1)  ·  M.D. Anderson Cancer Center (1)  ·  Matthew J. Frigault, M.D. (1)  ·  Nathan Denlinger (1)  ·  NeoImmuneTech (1)  ·  SWOG Cancer Research Network (1)  ·  Stanford University (1)

Countries

United States (10)

Top investigators

Brian T Hess (1)  ·  Edmund K Waller, MD, PhD (1)  ·  John DiPersio, M.D. (1)  ·  Matthew J. Frigault, MD (1)  ·  Nathan Denlinger, DO (1)  ·  Partow Kebriaei (1)  ·  Veronika Bachanova, MD (1)  ·  Veronika Bachanova, MD, PhD (1)

Results publications

PMID 38022532, PMID 41671463

NIH funding

P30CA138292 (1), U10CA180888 (1)